DCPH - Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now February, 11 2022 04:35 AM Deciphera Pharmaceuticals Inc. Deciphera's ripretinib failed a critical trial. The stock has been decimated. Although the company is struggling to make a comeback, it will take time. For further details see: Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now